Research Article

Bmi1 Severs as a Potential Tumor-Initiating Cell Marker and Therapeutic Target in Esophageal Squamous Cell Carcinoma

Figure 5

Treatment effect of cisplatin combined with PTC-209 on ESCC. (a, b) From left to right, the histopathology (a) and histogram (b) of ESCC in the control group, cisplatin-treated group, PTC-209-treated group, and the cisplatin+PTC-209-treated group. The processing time of the four groups was four weeks. Cisplatin combined with PTC-209 has the lowest malignancy. , , and . Scale bars are 100 μm.
(a)
(b)